Inherited antithrombin deficiency: a review

Haemophilia - Tập 14 Số 6 - Trang 1229-1239 - 2008
Mrinal M. Patnaik1, Stephan Moll2
1Department of Internal Medicine, University of Minnesota School of Medicine, Minneapolis, MN
2Division of Hematology-Oncology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA

Tóm tắt

Summary.  Antithrombin (AT) is a potent inactivator of thrombin and factor Xa and the major inhibitor of blood coagulation. Inherited AT deficiencies are uncommon, with prevalences in the general population between 1 in 500 and 1 in 5000. They are either quantitative (type I) or qualitative (type II). Type II is subdivided into the more common, but less thrombogenic, type IIb deficiency caused by a defect in the heparin‐binding region of AT and the less common, but more thrombophilic, type IIa variant caused by mutations in the thrombin‐binding site. A pleiotropic type IIc deficiency also exists. In the evaluation of a thrombophilic individual, a functional AT assay (AT activity) should be used and the diagnosis of AT deficiency only established after acquired causes have been ruled out and repeat AT testing on an additional sample has been performed. A subsequent antigenic AT assay result leads to differentiation between type I and type II deficiency. Further specialized tests help subclassify the type II deficiencies, but this is typically not carried out for clinical purposes, even though it might be helpful to assess thrombosis risk. AT deficiency is associated with an increased risk for venous thromboembolism (VTE) and pregnancy loss. The association with arterial thrombosis is only weak. VTE prophylaxis and treatment management will be discussed in this article and existing treatment guidelines presented. The lack of data surrounding the use of AT concentrates and the resulting ambiguity as to when to use such concentrates will be discussed.

Từ khóa


Tài liệu tham khảo

10.1038/nsmb811

10.1074/jbc.M607204200

10.1111/j.1365-2141.1994.tb04878.x

10.1002/ajh.2830450409

Finazzi G, 1987, Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases, Thromb Haemost, 18, 1094

10.1111/j.1365-2141.1993.tb03104.x

10.1055/s-0038-1655930

10.7326/0003-4819-138-2-200301210-00014

10.5858/2002-126-1326-AD

10.1046/j.1365-2141.2001.02981.x

10.2165/00003495-200767100-00005

10.1111/j.1538-7836.2005.01197.x

10.1182/blood.V92.7.2353

10.1161/01.ATV.19.4.1026

10.1111/j.1365-2141.2005.05847.x

10.1002/ajh.2830460218

10.1016/S0140-6736(96)04125-6

10.1111/j.1538-7836.2004.00662.x

10.1182/blood-2001-11-0047

10.1097/00001721-199610000-00005

10.7326/0003-4819-116-9-754

10.1097/00001721-199801000-00009

Bauersachs R, 2007, Perioperative bridging with fondaparinux in a woman with antithrombin deficiency, Thromb Haemost, 97, 498, 10.1160/TH06-10-0598

10.1046/j.1537-2995.2003.00315.x

10.1055/s-0038-1646334

Van Den Belt AG, 1997, Recurrence of venous thromboembolism in patients with familial thrombophilia, Arch Intern Med, 157, 2227, 10.1001/archinte.1997.00440400077009

10.1378/chest.126.3_suppl.401S

10.1111/j.1447-0756.2001.tb01250.x

10.1378/chest.08-0761

10.1016/0002-9343(89)80533-9

Menache D, 1990, Evaluation of the safety, recovery, half‐life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency, Blood, 75, 33, 10.1182/blood.V75.1.33.33

Edmunds T, 1998, Transgenically produced human antithrombin: structural and functional comparison to human plasma‐derived antithrombin, Blood, 91, 4561, 10.1182/blood.V91.12.4561

10.1378/chest.08-0658

Thông tin
Thông tin xuất bản

Haemophilia

Tập 14 Số 6

1229-1239

Thông tin tác giả